Tinne Verhulst

Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor

Timothy Perera, Eleonora Jovcheva, Laurence Mévellec et al. · Molecular Cancer Therapeutics · 2017 · 340 citations · Full text

Medicine, Oncology, Pharmacology +17

Inhibition of Histone Deacetylases by Chlamydocin Induces Apoptosis and Proteasome-Mediated Degradation of Survivin

Stefanie De Schepper, Hélène Bruwiere, Tinne Verhulst et al. · Journal of Pharmacology and Experimental Therapeutics · 2003 · 81 citations

Life Sciences, Cell Biology, Molecular Biology +17

Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in <i>KMT2A</i>- and <i>NPM1</i>-altered leukemias

Min Chul Kwon, Jan Willem Thuring, Olivier Querolle et al. · Blood · 2024 · 59 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +4

Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-&amp;alpha;-positive breast cancer

Kate Sasser, Tineke Casneuf, Amy Axel et al. · Breast Cancer Targets and Therapy · 2016 · 27 citations · Full text

Medicine, Cancer Biology, Oncology +15

Abstract DDT02-04: A novel PRMT5 inhibitor with potent in vitro and in vivo activity in preclinical lung cancer models

Dirk Brehmer, Tongfei Wu, Geert Mannens et al. · Cancer Research · 2017 · 20 citations

Medicine, Oncology, Pharmacology +13